한글목차

세계 폐쇄형 약물 전달 기기(CSTD) 시장 규모는 2025년 14억 9,000만 달러에서 2030년까지 20억 9,000만 달러에 달하고, 7.0%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

의료진의 안전에 대한 인식과 관심이 높아짐에 따라 폐쇄형 약물 전달 기기(CSTD)에 대한 시장 수요가 증가하고 있습니다. 의료기관은 안전 조치를 취하고 안전하지 않은 약물을 취급하는 위험으로부터 의료진을 보호하기 위해 이러한 장치에 많은 비용을 지출하고 있습니다. 따라서 이러한 수요 증가는 의료시설이 인력을 확보하기 위해 안전 조치를 취하는 것을 우선시하기 때문에 폐쇄형 약물 전달 기기(CSTD) 시장의 성장을 가속할 것으로 보입니다.

폐쇄 메커니즘별로는 컬러-투-컬러 정렬 시스템 부문이 폐쇄 시스템 이송 장치 시장에서 가장 높은 CAGR로 증가할 것으로 예측됩니다.

구성 요소별로는 바이알 액세스 부문이 폐쇄형 약물 전달 기기(CSTD) 시장에서 가장 큰 시장 점유율을 차지했습니다. 바이알 액세스 구성 요소는 의료진의 바늘에 찔릴 위험을 줄이고 이송 중 약물 오염을 방지하는 중요한 기능을 가지고 있습니다. 또한, 취급이 용이하여 신속한 약품 조제가 가능하며, 개방형 시스템과 관련된 오류의 위험을 최소화할 수 있습니다. 따라서 안전 및 효율성 요구 사항을 충족하는 바이알 액세스 구성 요소 부문이 시장을 주도할 가능성이 높습니다.

최종 사용자별로는 병원 및 클리닉이 폐쇄형 약물 전달 기기(CSTD) 시장을 독점하고 있습니다. 다른 의료 시설과 달리 병원 및 클리닉은 의료 장비에 대한 예산이 큽니다. 따라서 규제와 모범 사례를 준수하면서 최신 CSTD 기술에 투자할 수 있습니다. 또한, 병원 및 클리닉은 약물 취급 및 직원 보호와 관련하여 더 엄격한 규제가 적용되고 있으며, CSTD는 위험한 약물에 노출될 위험을 줄이고 투약 오류를 방지함으로써 이러한 요구를 충족시키는 데 도움이 됩니다.

북미는 예측 기간 동안 폐쇄형 약물 전달 기기(CSTD) 시장에서 가장 큰 점유율을 차지할 것으로 예측됩니다. 이는 의료진의 안전한 약물 취급의 중요성에 대한 인식이 높아진 데다, 의료 인프라가 잘 구축되어 있고 엄격한 규제 요건이 적용되고 있기 때문입니다. 이 지역은 환자 치료와 안전을 향상시키는 정교한 의료 기술 채택을 선도하고 있습니다.

세계의 폐쇄형 약물 전달 기기(CSTD) 시장에 대해 조사 분석했으며, 주요 촉진요인과 저해요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 조사 결과

• 폐쇄형 약물 전달 기기(CSTD) 시장 개요
• 아시아태평양의 폐쇄형 약물 전달 기기(CSTD) 시장 : 국가별, 기술별(2024년)
• 폐쇄형 약물 전달 기기(CSTD) 시장 : 지역 구성
• 폐쇄형 약물 전달 기기(CSTD) 시장 : 신흥 국가 시장 vs. 선진국 시장
• 폐쇄형 약물 전달 기기(CSTD) 시장 : 지역 목표 성장 기회

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
  • 평균 판매 가격 동향 : 컴포넌트별
  • 평균 판매 가격 동향 : 주요 기업별
  • 평균 판매 가격 동향 : 지역별
• 밸류체인 분석
  • 조사와 제품 개발
  • 재료 성분 조달과 제조
  • 마케팅, 세일즈, 출하, 애프터서비스
• 공급망 분석
• 생태계 분석
• 투자 및 자금조달 시나리오
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 산업 동향
• 특허 분석
• 무역 데이터 분석
  • 수입 데이터
  • 수출 데이터
• 주요 컨퍼런스 및 이벤트(2025년-2026년)
• 사례 연구 분석
  • 사례 연구 1: 마운트 사이나이 병원에서 1회용 바이알의 사용 기한 연장
  • 사례 연구 2: 네브라스카 메소디스트 병원의 약물 조제 안전성 및 효율성 향상
  • 사례 연구 3: 시뮬레이션된 최악의 시나리오에서 미생물 오염 방지
  • 규제 상황
    • 규제 기준 및 승인
    • 규제기관, 정부기관 및 기타 조직
  • Porter의 Five Forces 분석
  • 주요 이해관계자와 구입 기준
  • 미충족 요구/최종사용자 기대
  • 폐쇄형 약물 전달 기기(CSTD) 시장에 대한 생성형 AI의 영향
  • 폐쇄형 약물 전달 기기(CSTD) 시장에 대한 미국 관세 규제의 영향
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카

  제6장 폐쇄형 약물 전달 기기(CSTD) 시장 : 폐쇄 기구별

  • 서론
  • LUER LOCK SYSTEMS
  • PUSH-TO-TURN SYSTEMS
  • CLICK-TO-LOCK SYSTEMS
  • COLOR-TO-COLOR ALIGNMENT SYSTEMS

  제7장 폐쇄형 약물 전달 기기(CSTD) 시장 : 유형별

  • 서론
  • MEMBRANE-TO-MEMBRANE SYSTEMS
  • NEEDLELESS SYSTEMS

  제8장 폐쇄형 약물 전달 기기(CSTD) 시장 : 컴포넌트별

  • 서론
  • VIAL ACCESS COMPONENTS
  • MALE LUERS
  • BAG SPIKES
  • FEMALE COMPONENTS
  • 기타 컴포넌트

  제9장 폐쇄형 약물 전달 기기(CSTD) 시장 : 기술별

  • 서론
  • 다이아프램 기반 디바이스
  • 컴파트먼트 디바이스
  • 공기 청정 및 여과 디바이스

  제10장 폐쇄형 약물 전달 기기(CSTD) 시장 : 최종사용자별

  • 서론
  • 병원 및 진료소
  • 종양 센터
  • 기타 최종사용자

  제11장 폐쇄형 약물 전달 기기(CSTD) 시장 : 지역별

  • 서론
  • 북미
    • 북미의 거시경제 전망
    • 미국
    • 캐나다
  • 유럽
    • 유럽의 거시경제 전망
    • 독일
    • 영국
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양의 거시경제 전망
    • 일본
    • 중국
    • 인도
    • 호주 및 뉴질랜드
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 라틴아메리카의 거시경제 전망
    • 브라질
    • 멕시코
    • 콜롬비아
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 중동 및 아프리카의 거시경제 전망
    • GCC 국가
    • 기타 중동 및 아프리카

  제12장 경쟁 구도

  • 개요
  • 주요 시장 진출기업의 전략/강점
  • 매출 분석(2020년-2024년)
  • 시장 점유율 분석(2024년)
  • 주요 기업 R&D 평가
  • 기업 평가와 재무 지표
  • 브랜드/제품 비교
  • 기업 평가 매트릭스 : 주요 기업(2024년)
  • 기업 평가 매트릭스 : 스타트업/중소기업(2024년)
  • 경쟁 시나리오

  제13장 기업 개요

  • 주요 기업
    • BD
    • ICU MEDICAL, INC.
    • B. BRAUN MELSUNGEN AG
    • JMS CO. LTD.
    • BAXTER
    • WEST PHARMACEUTICAL SERVICES, INC.
    • TERUMO CORPORATION
    • CARDINAL HEALTH
    • EQUASHIELD
    • SIMPLIVIA HEALTHCARE LTD.
    • YUKON MEDICAL
    • CODAN MEDIZINISCHE GERATE GMBH
    • VYGON
    • ELCAM MEDICAL
    • PRACTIVET, INC.
  • 기타 기업
    • CARAGEN
    • CORVIDA MEDICAL
    • VICTUS
    • EPIC SYSTEMS CORPORATIONS
    • ERASER MEDICAL
    • NEEDLELESS CORPORATION
    • AMSINO INTERNATIONAL, INC.
    • INSUNG MEDICAL CO., LTD.
    • ADVCARE MEDICAL, INC.
    • SHANDONG ANDE HEALTHCARE APPARATUS CO., LTD.

  제14장 부록

  LSH

영문목차

The closed system transfer devices (CSTDs) market is projected to reach USD 2.09 billion by 2030, from USD 1.49 billion in 2025, at a CAGR of 7.0%.

With the increased consciousness and interest in the safety of healthcare workers, there is an increasing market demand for closed system transfer devices. Healthcare institutions are spending more on these devices to advance safety procedures and shield their workers against the dangers of working with unsafe drugs. This rising demand will, therefore, boost the growth of the closed system transfer devices market as healthcare facilities prioritize taking safety measures to secure their workforce.

Depending on the closing mechanism, the color-to-color alignment system segmented shall increase at the highest CAGR in the closed system transfer devices market.

On the basis of components, the vial access segment held the largest market share of the closed system transfer devices market. Vial access components have a crucial function in reducing the risk of needlestick injury among healthcare professionals and avoiding drug contamination while transferring. Additionally, ease of handling enables quick medication preparation and minimizes the risk of errors related to open systems. Thus, addressing safety and efficiency requirements, the vial access components segment is likely to drive the market.

Based on the end-user segment, the hospitals & clinics subsegment is dominated the closed system transfer devices market. In contrast to other medical facilities, hospitals and clinics have a bigger budget for medical equipment. This gives them the capability to spend on the newest CSTD technology while keeping abreast with regulations and best practices. Further, hospitals and clinics are under more rigid regulations on handling medication and employee protection. CSTDs assist them in fulfilling these needs by reducing the risk of exposure to dangerous drugs and avoiding medication errors.

North America is expected to account for the largest share of the closed system transfer devices market during the forecast period. This is due to the increased awareness by healthcare professionals towards the significance of the safe handling of drugs as well as a well-established infrastructure of healthcare and rigorous regulatory requirements. The region has been leading in the adoption of sophisticated medical technology to improve patient care and safety.

A breakdown of the primary participants (supply-side) for the closed system transfer devices market referred to for this report is provided below:

• By Company Type: Tier 1: 42%, Tier 2: 37%, and Tier 3: 21%
• By Designation: C-level: 39%, Director Level: 33%, and Others: 28%
• By Region: North America: 64%, Europe: 17%, Asia Pacific: 7%, Latin America: 6%, Middle East & Africa: 6%

Prominent players in the closed system transfer device market are BD (US), ICU Medical, Inc. (US), EQUASHIELD (US), JMS Co. Ltd. (Japan), Baxter (US), B Braun Melsungen AG (Germany), West Pharmaceuticals Services, Inc. (US) and Terumo Corporation (Japan).

Research Coverage

The report evaluates the closed system transfer devices market and estimates the market size and future growth potential based on various segments, including closing mechanism, type, component, technology, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will assist the market leaders/new entrants with data on the nearest approximations of the revenue numbers for the overall closed system transfer devices market and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights to better place their businesses and make appropriate go-to-market strategies. The report assists the stakeholders in understanding the market pulse and gives them data on influential drivers, hindrances, obstacles, and opportunities in the market.

This report provides insights into the following points:

• Analysis of key drivers (growing incidence of cancer and subsequent use of chemotherapy, Increasing regulatory approvals for oncology therapeutics, rising awareness about risks associated with handling antineoplastic drugs, stringent regulatory guidelines for handling hazardous medication), restraints (high implementation costs and limited reimbursements, Inconsistent regulatory compliance), opportunities (growth potential across therapeutic applications, rising healthcare expenditure in emerging economies) and challenges (impact of closed system transfer devices on drug quality, low awareness and poor implementation of protective measures)
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global closed system transfer devices market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by closing mechanism, type, component, technology, end user, and region
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global closed system transfer devices market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global closed system transfer devices market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 SCOPE-RELATED LIMITATIONS
  • 2.6.2 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CLOSED SYSTEM TRANSFER DEVICES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TECHNOLOGY AND COUNTRY, 2024
• 4.3 CLOSED SYSTEM TRANSFER DEVICES MARKET: REGIONAL MIX
• 4.4 CLOSED SYSTEM TRANSFER DEVICES MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS
• 4.5 CLOSED SYSTEM TRANSFER DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing incidence of cancer and subsequent use of chemotherapy
    • 5.2.1.2 Increasing regulatory approvals for oncology therapeutics
    • 5.2.1.3 Rising awareness about risks associated with handling antineoplastic drugs
    • 5.2.1.4 Stringent regulatory guidelines for handling hazardous medication
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High implementation costs and limited reimbursements
    • 5.2.2.2 Inconsistent regulatory compliance
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth potential across therapeutic applications
    • 5.2.3.2 Rising healthcare expenditure in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Impact of closed system transfer devices on drug quality
    • 5.2.4.2 Low awareness and poor implementation of protective measures
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY COMPONENT
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.5.2 MATERIAL COMPONENT PROCUREMENT AND MANUFACTURING
  • 5.5.3 MARKETING & SALES, SHIPMENT, AND AFTERSALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Needle-free systems
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Integration of sensors
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Advancements in containments
• 5.10 INDUSTRY TRENDS
  • 5.10.1 INTEGRATION OF FILTERS IN CLOSED SYSTEM TRANSFER DEVICES
  • 5.10.2 AUTOMATION OF TRANSFER PROCESSES
  • 5.10.3 ADVANCED MATERIALS FOR DURABILITY AND COMPATIBILITY WITH COMPLEX DRUG FORMULATIONS
• 5.11 PATENT ANALYSIS
• 5.12 TRADE DATA ANALYSIS
  • 5.12.1 IMPORT DATA
  • 5.12.2 EXPORT DATA
• 5.13 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 CASE STUDY 1: EXTENSION OF BEYOND-USE DATE OF SINGLE-DOSE VIALS AT MOUNT SINAI HOSPITAL
  • 5.14.2 CASE STUDY 2: ENHANCED SAFETY AND EFFICIENCY OF DRUG COMPOUNDING AT NEBRASKA METHODIST HOSPITAL
  • 5.14.3 CASE STUDY 3: PREVENTION OF MICROBIAL CONTAMINATION DURING SIMULATED WORST-CASE SCENARIOS
• 5.15 REGULATORY LANDSCAPE
  • 5.15.1 REGULATORY STANDARDS AND APPROVALS
    • 5.15.1.1 US
      • 5.15.1.1.1 USP <800> Regulations
      • 5.15.1.1.2 National Institute for Occupational Safety and Health
      • 5.15.1.1.3 American Society of Health-System Pharmacists
      • 5.15.1.1.4 International Society of Oncology Pharmacy Practitioners
    • 5.15.1.2 European Union
  • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.16 PORTER'S FIVE FORCES ANALYSIS
  • 5.16.1 BARGAINING POWER OF SUPPLIERS
  • 5.16.2 BARGAINING POWER OF BUYERS
  • 5.16.3 THREAT OF NEW ENTRANTS
  • 5.16.4 THREAT OF SUBSTITUTES
  • 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.17.2 BUYING CRITERIA
• 5.18 UNMET NEEDS/END-USER EXPECTATIONS
• 5.19 IMPACT OF GEN AI ON CLOSED SYSTEM TRANSFER DEVICES MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 MARKET POTENTIAL OF AI IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
  • 5.19.3 AI USE CASES
  • 5.19.4 KEY COMPANIES IMPLEMENTING AI
  • 5.19.5 FUTURE OF GENERATIVE AI IN CLOSED SYSTEM TRANSFER DEVICES MARKET
• 5.20 IMPACT OF US TARIFF REGULATION ON CLOSED SYSTEM TRANSFER DEVICES MARKET
  • 5.20.1 NORTH AMERICA
  • 5.20.2 EUROPE
  • 5.20.3 ASIA PACIFIC
  • 5.20.4 LATIN AMERICA
  • 5.20.5 MIDDLE EAST & AFRICA

6 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM

• 6.1 INTRODUCTION
• 6.2 LUER LOCK SYSTEMS
  • 6.2.1 GROWING PREVALENCE OF INJECTABLE DRUGS TO PROPEL MARKET
• 6.3 PUSH-TO-TURN SYSTEMS
  • 6.3.1 INCREASING FOCUS ON COMPLYING WITH REGULATIONS AND GUIDELINES FOR SAFE HANDLING OF DRUGS TO AID GROWTH
• 6.4 CLICK-TO-LOCK SYSTEMS
  • 6.4.1 LOW IMPLEMENTATION COST TO CONTRIBUTE TO GROWTH
• 6.5 COLOR-TO-COLOR ALIGNMENT SYSTEMS
  • 6.5.1 GROWING FOCUS ON CURBING RISK OF MEDICATION ERRORS TO FUEL MARKET

7 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 MEMBRANE-TO-MEMBRANE SYSTEMS
  • 7.2.1 INCREASING FOCUS ON SAFEGUARDING HEALTH AND WELL-BEING OF HEALTHCARE PROVIDERS TO EXPEDITE GROWTH
• 7.3 NEEDLELESS SYSTEMS
  • 7.3.1 EVOLVING MEDICAL DEVICE TECHNOLOGY LANDSCAPE TO STIMULATE GROWTH

8 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY COMPONENT

• 8.1 INTRODUCTION
• 8.2 VIAL ACCESS COMPONENTS
  • 8.2.1 GROWING CONCERNS SURROUNDING HEALTHCARE-ASSOCIATED INFECTIONS TO DRIVE MARKET
• 8.3 MALE LUERS
  • 8.3.1 NEED TO PREVENT AIR EMBOLISM AND PRESERVE INTEGRITY OF INTRAVENOUS SYSTEMS TO PROMOTE GROWTH
• 8.4 BAG SPIKES
  • 8.4.1 GROWING FOCUS ON ENHANCED SAFETY, EFFICIENCY, AND PRECISION IN HANDLING AND ADMINISTRATING HAZARDOUS DRUGS TO BOOST MARKET
• 8.5 FEMALE COMPONENTS
  • 8.5.1 NEED TO PREVENT CONTAMINATION OF DRUGS AND EQUIPMENT TO ENCOURAGE GROWTH
• 8.6 OTHER COMPONENTS

9 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 DIAPHRAGM-BASED DEVICES
  • 9.2.1 INCREASING USE OF DIAPHRAGM-BASED DEVICES IN CHEMOTHERAPY AND OTHER ONCOLOGY TREATMENTS TO FOSTER GROWTH
• 9.3 COMPARTMENTALIZED DEVICES
  • 9.3.1 NEED TO MAINTAIN INTEGRITY OF MEDICATIONS DURING TRANSFER TO SUSTAIN GROWTH
• 9.4 AIR CLEANING/FILTRATION DEVICES
  • 9.4.1 NEED FOR CLEAN AND STERILE ENVIRONMENT WITHIN PHARMACEUTICAL AND HEALTHCARE FACILITIES TO FACILITATE GROWTH

10 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 GROWING FOCUS ON ENHANCED STAFF AND PATIENT SAFETY IN HEALTHCARE SETTINGS TO BOOST MARKET
• 10.3 ONCOLOGY CENTERS
  • 10.3.1 NEED TO MINIMIZE RISK OF OCCUPATIONAL EXPOSURE TO AUGMENT GROWTH
• 10.4 OTHER END USERS

11 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising focus on best practice recommendations and mandates for healthcare workers to aid growth
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing demand for antineoplastic drugs to assist growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Growing emphasis on healthcare protocols to propel market
  • 11.3.3 UK
    • 11.3.3.1 Strict guidelines for handling hazardous drugs to promote growth
  • 11.3.4 FRANCE
    • 11.3.4.1 High healthcare expenditure to accelerate growth
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing incidence of cancer to favor growth
  • 11.3.6 ITALY
    • 11.3.6.1 Rising geriatric population and subsequent prevalence of chronic diseases to aid growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Established healthcare system and rising geriatric population to drive market
  • 11.4.3 CHINA
    • 11.4.3.1 Large target patient population to stimulate growth
  • 11.4.4 INDIA
    • 11.4.4.1 Rising adoption of chemotherapy procedures to facilitate growth
  • 11.4.5 AUSTRALIA AND NEW ZEALAND
    • 11.4.5.1 Rising incidence of chronic diseases to speed up growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Shift to aging demography to spur growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Booming healthcare and pharmaceutical sectors to amplify growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising initiatives on universal healthcare coverage to support growth
  • 11.5.4 COLOMBIA
    • 11.5.4.1 Growing prioritization of patient and worker safety to bolster growth
  • 11.5.5 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Higher disposable incomes to expedite growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 R&D ASSESSMENT OF KEY PLAYERS
• 12.6 COMPANY VALUATION AND FINANCIAL METRICES
• 12.7 BRAND/PRODUCT COMPARISON
  • 12.7.1.1 BD
  • 12.7.1.2 ICU Medical, Inc.
  • 12.7.1.3 B. Braun Melsungen AG
  • 12.7.1.4 JMS Co. Ltd.
  • 12.7.1.5 Baxter
  • 12.7.1.6 EQUASHIELD
• 12.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.8.1 STARS
  • 12.8.2 EMERGING LEADERS
  • 12.8.3 PERVASIVE PLAYERS
  • 12.8.4 PARTICIPANTS
  • 12.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.8.5.1 Company footprint
    • 12.8.5.2 Region footprint
    • 12.8.5.3 Closing mechanism footprint
    • 12.8.5.4 Type footprint
    • 12.8.5.5 Component footprint
    • 12.8.5.6 Technology footprint
    • 12.8.5.7 End-user footprint
• 12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.9.1 PROGRESSIVE COMPANIES
  • 12.9.2 RESPONSIVE COMPANIES
  • 12.9.3 DYNAMIC COMPANIES
  • 12.9.4 STARTING BLOCKS
  • 12.9.5 COMPETITIVE BENCHMARKING
    • 12.9.5.1 Detailed list of key startups/SMEs
    • 12.9.5.2 Competitive benchmarking of key startups/SMEs
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 BD
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 ICU MEDICAL, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 B. BRAUN MELSUNGEN AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches and approvals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 JMS CO. LTD.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Right to win
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses and competitive threats
  • 13.1.5 BAXTER
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 WEST PHARMACEUTICAL SERVICES, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Expansions
  • 13.1.7 TERUMO CORPORATION
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Expansions
  • 13.1.8 CARDINAL HEALTH
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 EQUASHIELD
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches and approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 SIMPLIVIA HEALTHCARE LTD.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 YUKON MEDICAL
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 CODAN MEDIZINISCHE GERATE GMBH
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 VYGON
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 ELCAM MEDICAL
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 PRACTIVET, INC.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER COMPANIES
  • 13.2.1 CARAGEN
  • 13.2.2 CORVIDA MEDICAL
  • 13.2.3 VICTUS
  • 13.2.4 EPIC SYSTEMS CORPORATIONS
  • 13.2.5 ERASER MEDICAL
  • 13.2.6 NEEDLELESS CORPORATION
  • 13.2.7 AMSINO INTERNATIONAL, INC.
  • 13.2.8 INSUNG MEDICAL CO., LTD.
  • 13.2.9 ADVCARE MEDICAL, INC.
  • 13.2.10 SHANDONG ANDE HEALTHCARE APPARATUS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS